Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al.
Sentinel node update#
Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial. 2008 15(5):1282–96.Ĭanavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, et al. Management of the axilla in women with breast cancer: current clinical practice and a new selective targeted approach. Samphao S, Eremin JM, El-Sheemy M, Eremin O. We also explore the data relevant to complete omission of SLNB in selected invasive breast cancer cases, in line with very recent randomised trials currently underway. In this chapter, we elaborate on the current concept of SLNB and review its extended indications. leading to omission of ALND) in breast cancers with low axillary nodal burden. Moreover, modern data suggest that SLNB may be adequate as a means of staging as well as of local control (i.e. In recent years, emerging data from landmark trials have extended the use of SLNB beyond its well-established scope, for instance in patients with node-positive breast cancer who receive primary systemic therapy. As a result, axillary node clearance (axillary lymph node dissection, ALND) has been abandoned as a staging procedure and is reserved for local control in certain cases of node-positive breast cancer. Cumulative evidence from randomized trials suggests that SLNB is accurate and safe in patients with early, clinically and radiologically node-negative disease. The technique of SLNB has been refined since its initial conception, and currently SLNB is a milestone of breast cancer surgical management. Sentinel lymph node biopsy (SLNB) remains the gold standard for regional axillary staging in early, clinically and radiologically node-negative breast cancer.
0 kommentar(er)
